BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 25, 2010
 |  BioCentury  |  Emerging Company Profile

Covagen: Building on a Human Backbone

Covagen AG believes its Fynomer technology has advantages over other protein scaffolds because it combines a conserved, human-derived backbone with amino acid characteristics that allow the proteins to be modified into a variety of formats. The company plans to develop its own pipeline of Fynomers for autoimmune or cancer indications through proof of concept before finding partners.

Fynomers are based on the naturally occurring human protein scaffold Fyn SH3-derived binding protein. Co-founder and CSO Dragan Grabulovski discovered Fynomers while completing his Ph.D. thesis in the lab of Dario Neri at the Swiss Federal Institute of Technology. Covagen has an exclusive license to the technology from the university.

Co-founder and CEO Julian Bertschinger believes the Fyn SH3 backbone has ideal properties for a scaffold technology, noting in particular that the protein is conserved...

Read the full 659 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >